Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
The CYBN news page on Stock Titan provides an archive of news releases and updates related to Cybin Inc., a Phase 3 clinical-stage neuropsychiatry and pharmaceutical company focused on developing next-generation treatment options for mental health conditions. These news items come directly from the company’s public communications and are also referenced in its Form 6-K filings with the U.S. Securities and Exchange Commission.
Readers can find coverage of Cybin’s clinical development programs, including updates on its lead candidates CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder, and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. News releases describe milestones such as trial enrollment progress, regulatory approvals to initiate studies in various countries, and participation in healthcare and investor conferences.
The news feed also includes information on Cybin’s capital markets activity, such as registered direct offerings of common shares and pre-funded warrants, the establishment and use of an at-the-market equity program, and the company’s stated intentions for the use of proceeds, including repayment of convertible debentures and funding of its clinical programs. Corporate updates, including plans to transfer its U.S. stock exchange listing from the NYSE American to the Nasdaq Global Market and the associated change in ticker symbol from CYBN to HELP, are documented in detail.
Because Cybin files many of these news releases as exhibits to Form 6-K, the CYBN news page serves as a convenient way to follow the narrative of its clinical progress, financing decisions, and listing changes over time. Investors and researchers can use this archive to review how the company describes its strategy in neuropsychiatry, its geographic operations in Canada, the United States, the United Kingdom, and Ireland, and its stated commitment to rigorous scientific research and regulatory compliance for its investigational compounds.
Cybin Inc. has launched EMBARK Open Access (EMBARK OA), a free online training course for psychedelic facilitation aimed at healthcare professionals.
This initiative is the first of its kind, promoting ethical psychological support and accessibility in psychedelic-assisted therapy. Participants can earn a Record of Completion, potentially leading to future training programs and involvement in Cybin-sponsored clinical studies.
Cybin's mission is to enhance mental healthcare through innovative psychedelic treatments, supported by expert faculty who created engaging training modules.
CEO Doug Drysdale emphasized their commitment to making training accessible, addressing the financial barriers present in existing programs.
Cybin Inc. (AMEX:CYBN) announced that CEO Doug Drysdale will participate in a virtual fireside chat during the Oppenheimer 33rd Annual Healthcare Conference from March 13-15, 2023. The live webcast is scheduled for March 14, 2023, at 12:40 p.m. ET. Interested parties can click here to access the live stream. Cybin is committed to developing safe, effective therapeutics for mental health issues and operates across various countries, focusing on innovative drug delivery and drug discovery for psychedelic-based therapies.
Cybin (AMEX:CYBN) will participate in the SXSW Conference from March 10-19, 2023, with CEO Doug Drysdale and wellness expert Deepak Chopra featured on a panel titled Open Minds: Innovations in Consciousness, Psychedelics & Mental Health on March 12, 2023.
The panel will explore the connection between consciousness, mental health, and psychedelic therapeutics. They will also discuss the upcoming miniseries Open Minds: Exploring Psychedelic Medicine, set to release on April 19, 2023, showcasing leading experts in the field.
Cybin Inc. (NYSE:CYBN) announced interim data from its Phase 1/2a clinical trial of CYB003, showing rapid, short-acting psychedelic effects at low doses with a robust safety profile. The trial completed Phase 1 dosing, progressing to Phase 2a, with top-line results expected by late Q3 2023. Additionally, positive findings from the CYB004-E trial suggest IV DMT was well-tolerated, with first-in-human dosing expedited. Cybin will host an R&D Day on
Cybin has announced a streamlining plan to enhance operational efficiency and focus on critical clinical trials. The company will reduce its workforce by approximately 15%, leading to anticipated cost savings and a significant decrease in its annual cash burn rate by millions of dollars. Cybin aims to support value-driving clinical milestones, particularly with its drug candidates CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder. A virtual R&D Day is scheduled for February 28, 2023, providing updates on its clinical development pipeline.
Cybin reported its third-quarter unaudited financial results for the period ending December 31, 2022, highlighting a net loss of C$10.7 million, a decrease from C$17.2 million in the prior year. Cash at the end of the quarter was C$22.5 million, which declined to C$20 million by February 14, 2023. Significant advances in clinical trials include the upcoming interim readout for CYB003 and the commencement of human trials for CYB004, both slated for their R&D Day on February 28, 2023. The company aims to optimize dosing strategies and leverage positive preclinical results to enhance its therapeutic offerings in mental health treatments.
Cybin Inc. has received approval to initiate first-in-human dosing of its proprietary molecule, CYB004, a deuterated form of DMT, during the ongoing CYB004-E Phase 1 trial in the Netherlands. This marks the first evaluation of deuterated DMT in humans, enhancing the understanding of its therapeutic benefits for generalized anxiety disorder. Preclinical studies indicate that CYB004 has improved bioavailability compared to traditional DMT, potentially allowing for less invasive dosing methods. Cybin holds a U.S. patent for CYB004, valid until 2041.
Cybin, a biopharmaceutical company focused on developing psychedelic therapies, will host a virtual R&D Day on February 28, 2023, from 10:00 a.m. ET to 11:30 a.m. ET. The event will showcase updates on Cybin's development pipeline, including interim results from the Phase 1/2a study of CYB003, targeted for treating major depressive disorder, and updates from the Phase 1 exploratory trial of CYB004 for generalized anxiety disorder. A Q&A session for investors will follow the presentation, and an archived webcast will be available afterward.
Cybin Inc. announced promising results from a feasibility study using Kernel Flow, a wearable technology designed to measure the psychedelic effects of ketamine on brain activity. Conducted in partnership with Kernel, the study found that Kernel Flow successfully provides real-time assessments of blood oxygenation changes linked to neural activity. Key findings included ketamine's impact on functional brain biomarkers and its potential utility in predicting therapeutic outcomes. Cybin aims to further explore psychedelics' effects for mental health treatments, holding exclusive rights to innovations from this study.
Cybin Inc. (AMEX:CYBN) has identified Generalized Anxiety Disorder (GAD) as a target indication for its proprietary DMT molecule, CYB004. Preclinical data suggests that CYB004 could effectively treat anxiety disorders, addressing a pressing need given the rising incidence of depression and anxiety, particularly following the pandemic. GAD affects over 40 million adults in the U.S., highlighting the urgency for innovative therapies. Cybin is currently conducting a Phase 1 exploratory trial to assess the safety and dosing of CYB004, with updates expected by the end of February 2023.